"Dear colleagues,
We are most delighted and honoured to organize the 38th meeting of the International Society of Oncology and BioMarkers (ISOBM) from 3rd to 8th September 2010 in München , Germany".

"München is the capital of Bavaria and – as is frequently said – the secret capital of Germany. München is a charming city with many faces, with a long-lasting tradition, historical buildings, a broad variety of cultural events and facilities and famous museums. Besides these fascinating facets, München is modern and “avantgarde” with highly developed technologies and industry".

"The Ludwig-Maximilians-University of München , where our congress will take place, is one of the Universities of Excellence in Germany. ISOBM 2010 will take place at our huge University Hospital Campus Großhadern , which offers a high standard of congress facilities and can be reached by subway within 15 minutes from the center of München".

"Our motto for ISOBM 2010 is":
'Biomarkers in Oncology – Leading the Path to Personalized Medicine'

"With your help and active contributions we hope to be able to cover a broad spectrum of diagnostic oncology with a clear focus on patient care. In addition to invited speakers, we will offer Poster Sessions and Sessions for free oral communications. We will also include several awards and support for young scientists. We would like to welcome ISOBM members and all scientists interested in the field of cancer research to attend ISOBM 2010 not only for contributing to a successful meeting but in order to make a step forward together in the difficult field of cancer disease research and management".

"We look forward to welcoming you cordially in München in September 2010,
Herzlich Willkommen und "Servus" in München".

Dr. Petra Stieber
Congress President

Institute of Clinical Chemnistry
Klinikum der Universität München
Campus Großhadern
Marchionini-Str . 15
D- 81377 München
Germany

Prof. Dr. Rolf Lamerz
Congress Vice President

Medical Department II
Klinikum der Universität München
Campus Großhadern
Marchionini-Str . 15
D- 81377 München
Germany

Dr. Heinz Bodenmüller
Scientific committee

Organizing committtee:
Andrea Baur-Melnyk
Heinz Bodenmüller
Alexander Burges
Volker Heinemann
Stefan Holdenrieder
Frank Kolligs
Volker Nüssler
Fritz Spelsberg
Michael Vogeser
Raphaela Waidelich

National advisory board:
Donna Ankerst
Manfred Dietel
Klaus Friese
Burkhard Goeke
Wolfgang Hiddemann
Karl-Walter Jauch
Thomas Kirchner
Maximilian Reiser
Andreas Schalhorn
Axel Semjonow
Christian Stief

International advisory board:
Gary Abelev (Russia)
Vivian Barak (Israel)
Hans Bonfrer (Netherlands)
Caroline Chapman (Great Britain)
Elefterios Diamandis (Canada)
Joe Duffy (Ireland)
Itoh Fumio (Japan)
Phil Gold (Canada)
Sten Hammarstrom (Sweden)
Yugi Hinoda (Japan)
Kohzoh Imai (Japan)
Herbert Kupchik (USA)
Masahide Kuroki (Japan)
Jean-Pierre Mach (Switzerland)
José Luis Millàn (USA)
Rafael Molina (Spain)
Ricardo Moro (Canada)
Marius Nap (Netherlands)
Andrea Nicolini (Italy)
Kjell Nustad (Norway)
Elisabeth Paus (Norway)
Marta Sanchez-Carbayo (Spain)
Stewart Sell (USA)
Jack Shively (USA)
Ulf Hakan Stenman (Finland)
Torgny Stigbrand (Sweden)
Cathie Sturgeon (Great Britain)
Minoru Toyota (Japan)
Tomas Zima (Czech Republic)

Confirmed Speaker on the ISOBM Congress:

M. Angele - München
D. Ankerst - München
C. Bangma - Rotterdam
V. Barak - Jerusalem
R. Bast - Texas
A. Bjartell - Lund
R. Büttner - Bonn
C. Chapman - Nottingham
S. Diederichs - Heidelberg
M. Dietel - Berlin
J. Duffy - Dublin
I. Esposito - München
L. Gold - Bolder
A. Graser - München
N. Harbeck - Köln
G. Hartung -Oldenburg
A. Haug - München
V. Heinemann - München
F. Herth - Heidelberg
T. Hoffmann - München
S. Holdenrieder - Bonn
H. Hondermark - Lille
D. Hoon - Santa Monica
I. Horvarth - Budapest
M. Huber - München
A. Jung - München
V. Jurinovic - München
A. Katalinic - Lübeck
M. Kattan - Cleveland
T. Kirchner - München
J. Kleeff - München
F. Kolligs - München
C. Kuhl - Aachen
R. Lamerz - München
R. Laubender - München
H. Lehrach - Berlin
H. Lilja - New York
T. Longerich - Heidelberg
F. Lottspeich - Martinsried
U. Mansmann - München
C. Marth - Innsbruck
D. Mayr - München
A. Meindl - München
U. Menon - London
H. Mitchell - London
R. Molina - Barcelona
R. Moro - Richmond
M. Nap - Heerlen
K. Nustad - Oslo
K. Pantel - Hamburg
E. Paus - Oslo
M. Pierotti - Mailand
M. Reiser - München
H. Rittenhouse - San Diego
M. Roobol - Rotterdam
P. Rudd - Dublin
M. Sanchez-Cabayo - Madrid
S. Sauerland - Köln
A. Schalhorn - München
B. Schwalb - München
A. Semjonow - Münster
R. Stahel - Zürich
U. Stenman - Helsinki
P. Stieber - München
T. Stigbrand - Umea
S. Stinzing - München
C. Sturgeon - Edinburgh
M. Toyota - Sapporo
R. Wirtz - Köln
C. Zech - München
M. Zichy - München

Program on Saturday 4th September 2010:

Opening Ceremony
08:30-09:00
Plenary Lecture
09:00-09:45
Cancer Genome
H. Lehrach - Berlin, DE

Biomarkers - When, Why, Which?
10:00-12:00
The burden of cancer - actual and future developments
A. Katalinic - Lübeck, DE

Criteria and Methods for Screening
S. Sauerland - Köln, DE

Criteria and Methods for Treatment Stratification
G. Hartung - Oldenburg, DE

Criteria and Methods for Monitoring Cancer Desease
A. Schalhorn - München, DE

Preanlytical and anlytical influences on valid reseach
C. Sturgeon - Edinburgh, UK

Lunch Symposium
12:10 - 13:10
Fujirebio Diagnostics, Inc

12:10 - 13:10
Siemens Healthcare Diagnostics GmbH

Genes and Nucleic Acids
14:10-16:25
Gene Mutations in Malignancies
M. Pierotti - Milano, IT

Beyond Proteins: Non-coding RNAs as Biomarkers in Cancer
S. Diederichs - Heidelberg, DE

Role of Circulating Nucleic Acids in the Managment of Cancer Patients
D. Hoon - US

Epigenetics as Cancer Biomarkers
M. Toyota - Sapporo, JP

Breast Cancer
14:10 - 17:00
Screening and Early Detection of Breast Cancer
C. Kuhl - Aachen, DE

Genetic Breast Cancer
A. Meindl - München, DE

Tissue Biomarkers for Prognosis and Treatment Stratification
M. Dietel - Berlin, DE

Criteria For Primary Treatment Decisions
N. Harbeck - Köln, DE

Early Detection of Metastatic Disease:
Blood Biomarkers
P. Stieber - München, DE

Imaging Biomarkers
M. Reiser - München, DE

Individualized Treatment of Metastatic Disease
V. Heinemann - München, DE

Round Table

Free Communications
16:35 - 18:35
Biomarkers in Basic Oncology

Free Communications
17:10 - 19:10
Biomarkers in Breast Cancer

Program on Sunday 5th September 2010:
Plenary Lecture
08:30-09:15
Cancer Proteomics
H. Hondermarck - Lille, FR

Pancreatic Cancer
09:30-11:50
Components of Pancreatic Cancer
J. Kleeff - München, DE

Increasing Role of PET and PET-CT for Pancreatic Cancer
A. Haug - München, DE

Clinical Value of Pathology in Diagnosis of Pancreatic Cancer
I. Esposito - München, DE

Serum Biomarkers in Pancreatic Cancer
J. Duffy - Dublin, IE

Role of CA19-9 in Chemotherapy Studies: Modelling, Prediction and Validation
U. Mansmann - München, DE

Targeted Therapy of PC: Response Predictable?
V. Heinemann - München, DE

Round Table

Proteins
09:30 - 11:50
Integrated Strategy for Identifying and Screening Potential Cancer Biomarkers
P. Rudd - Dublin, IE

Autoantibodies in Oncology – an overview
C. Chapman - Nottingham, UK

Unlocking Biomarker Discovery for Early Detection of Lung Cancer
L. Gold - Boulder, US

Proteomic profiling in breath
I. Horvath - Budapest, HU

Lunch Symposium
12:00 - 13:00
Abbott Diagnostics

Lung Cancer
14:00-16:30
Screening and Early Detection for Lung Cancer - Hope and Reality
R.M. Huber - München, DE

Screening in Clinical Practice - a Japanese Experiance
N.N.

Endoscopy and Imaging: Their Contributuions in LC Diagnosis
F. Herth - Heidelberg, DE

Pathology: Improvements with Molecular Markers -
Where are the Gaps?
R. Büttner - Bonn, DE

Therapy: Biologics as New Therapeutics
R. Stahel - Zürich, CH

Serology: Contribution in Primary Diagnosis and Monitoring
S. Holdenrieder - Bonn, DE

Round Table

Free Communications
14:00 - 16:15
Predictive Biomarkers

Free Communications
16:20 - 18:45
Biomarkers in Gastrointestinal Cancer

Free Communications
16:30 - 18:30
Biomarkers in Lung Cancer

ISOBM General Assembly
19:30-22:00
Hofbräuhaus München

Program on Monday 6th September 2010:

Plenary Lecture
08:30-09:15
Personalized medicine - ethical considerations
M. Zichy - München, DE

Liver Cancer
9:30 - 12:00
Surveillance for and of HCC by Molecular Biomarkers
R. Lamerz - München, DE

Diagnosis of HCC by Imaging Biomarkers: US, CT and MRI
C. Zech

HCC Diagnosis by Tissue Biomarkers in Pathology
T. Longerich - Heidelberg, DE

Treatment of HCC:

Resection and Transplantation
M. Angele - München, DE

RFTA / PEI and TACE
R. T. Hoffmann - München, DE

Targeted Molecular Therapy of HCC
F. Kolligs - München, DE

Round Table

Free Communications
09:30 - 11:30
Biomarker in Ovarian Cancer

Abbott Award Lecture
12:00-13:00

Program on Tuesday 7th September 2010:
Plenary Lecture
08:30-09:15
Stem Cells
T. Kirchner - München, DE

Ovarian Cancer
9:30 - 12:00
Biomarkers in Screening and Early Detection
U. Menon - London, UK

Biomarkers to Aid in Distinguishing Malignant from Benign Pelvic Masses
R. Bast - Texas, US

Biomarkers in Tissue
D. Mayr - München, DE

Biomarkers for Prognosis and Prediction
R. Wirtz - Köln, DE

Biomarkers for Monitoring Ovarian Cancer: Benefit or Harm?
Ch. Math - Innsbruck, AT

Round Table

Free Communications
09:30 - 11:30
Biomarker in Urological Cancers
Lunch Symposium
12:10 - 13:10
Roche Diagnostics
Colorectal Cancer
14:10 - 17:10
Screening of Colorectal Cancer -
Stool Tests (g/iFOBT versus DNA Test)
J. Duffy - Dublin, IE

Colonoscopy versus Colonography (CT. MRI)
A. Graser - München, DE

Epigenetic Biomarkers in Colorectal Cancer
F. Kolligs - München, DE

Proteomic Biomarkers in Colorectal Cancer
F. Lottspeich - Martinsried, DE

Testing of Predictive Biomarkers in Molecular Pathology for Targeted Therapies
A. Jung - München, DE

Targeted Therapy of Colorectal Cancer
S. Stintzing - München, DE

Clinical Relevance of Early Detection of Recurrent Colorectal Cancer During Follow-up Care
V. Heinemann - München, DE

Round Table

Biostatistics - Workshop
14:10-17:10
Statistical Evaluation of a Novel Marker
M. Kattan - Cleveland, US

Latest Progress and Enhancements to the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator
D. Ankerst - München, DE

Visual exploration of data in laboratory medicine, a way to discover differences and similarities in categories of sex, age, primary diagnosis and follow up profiles within and between Laboratories
M. Nap - NL

Discovery and validation: two essential steps in biomarker research
V. Jurinovic - München, DE

The Dynamics of mRNA Synthesis and Decay during the osmotic Stress Response in Yeast
B. Schwalb - München, DE

Cancer Markers: A scientist’s approach to merging statistics with common sense
R. Moro - Richmond, CA

Panel Discussion on new ISOBM Statistics Committee
D. Ankerst, Mike Kattan, Ricardo Moro

Program on Wednesday 8th September 2010:
Plenary Lecture

08:30-09:15
Disseminated Tumor Cells
K. Pantel - Hamburg, DE

Time of Change in Prostate Cancer?
09:30-12:30
How to Identify Men Who Profit from Screening for PCa?
C. Bangma - Rotterdam, NL

Comparison of Various Risk Calculators for PCa
M. Roobol - Rotterdam, NL

What Could Be the Future in PCa Diagnostics?
H. Rittenhouse - US

What Can We Expect from -2proPSA?
A. Semjonow - Münster, DE
Monitoring of PCa by Biomarkers
A. Bjartell - Lund, SE

A Holistic View on Diagnosis and Treatment of Men with PCa
H. Lilja, US

Round Table

Closing Ceremony
12:45-13:00

ISOBM New Board Meeting
13:30-15:00

Info: isobm2010.de
http://www.isobm2010.de/home-isobm2010.html